Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025
Diamyd Medical will present analyses of clinical data from trials in Type 1 Diabetes evaluating the investigational precision immunotherapy Diamyd[®] (rhGAD65/alum) at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Amsterdam, the Netherlands. The analyses, highlighting significant correlation between C-peptide secretion and glycemic benefits in Type 1 Diabetes, are part of the ongoing preparations ahead of Diamyd Medical’s Phase 3 readout expected around March 2026 where C-peptide will serve as the primary endpoint to support a potential accelerated Biologics License